2644Accesses
12Altmetric
ALetter to the Editor to this article was published on 09 October 2021
ALetter to the Editor to this article was published on 09 October 2021
Abstract
Exertional heat stroke (EHS) and malignant hyperthermia (MH) are life-threatening conditions, triggered by different environmental stimuli that share several clinical symptoms and pathophysiological features. EHS manifests during physical activity normally, but not always, in hot and humid environments. MH manifests during exposure to haloalkane anesthetics or succinylcholine, which leads to a rapid, unregulated release of calcium (Ca2+) within the skeletal muscles inducing a positive-feedback loop within the excitation–contraction coupling mechanism that culminates in heat stroke-like symptoms, if not rapidly recognized and treated. Rare cases of awake MH, independent of anesthesia exposure, occur during exercise and heat stress. It has been suggested that EHS and MH are mediated by similar mechanisms, including mutations in Ca2+ regulatory channels within the skeletal muscle. Rapid cooling, which is the most effective treatment for EHS, is ineffective as an MH treatment; rather, a ryanodine receptor antagonist drug, dantrolene sodium (DS), is administered to the victim to prevent further muscle contractions and hyperthermia. Whether DS can be an effective treatment for EHS victims remains uncertain. In the last decade, multiple reports have suggested a number of mechanistic links between EHS and MH. Here, we discuss aspects related to the pathophysiology, incidence, diagnosis and treatment. Furthermore, we present evidence regarding potential overlapping mechanisms between EHS and MH and explore current knowledge to establish what is supported by evidence or a lack thereof (i.e. conjecture).
This is a preview of subscription content,log in via an institution to check access.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
Buy Now
Price includes VAT (Japan)
Instant access to the full article PDF.

Similar content being viewed by others
References
Tobin JR. Malignant hyperthermia and apparent heat stroke. JAMA. 2001;286:168.
Leon LR, Bouchama A. Heat stroke. Compr Physiol. 2015;5:611–47.
Sawka MN, Leon LR, Montain SJ, Sonna LA. Integrated physiological mechanisms of exercise performance, adaptation, and maladaptation to heat stress. Compr Physiol. 2011;1:1883–928.
Roberts WO. Exertional heat stroke during a cool weather marathon: a case study. Med Sci Sports Exerc. 2006;38:1197–203.
Ellinas H, Albrecht MA. Malignant hyperthermia update. Anesthesiol Clin. 2020;38:165–81.
Appiah-Ankam J, Hunter JM. Pharmacology of neuromuscular blocking drugs. Contin Educ Anaesth Crit Care Pain. 2004;4:2–7.
Jardon OM. Physiologic stress, heat stroke, malignant hyperthermia—a perspective. Mil Med. 1982;147:8–14.
Lavezzi WA, Capacchione JF, Muldoon SM, Sambuughin N, Bina S, Steele D, et al. Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg. 2013;116:420.
Figarella-Branger D, Kozak-Ribbens G, Rodet L, Aubert M, Borsarelli J, Cozzone PJ, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord. 1993;3:553–6.
Ogletree JW, Antognini JF, Gronert GA. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med. 1996;24:49–51.
Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: awake episodes and correction by Dantrolene. Anesth Analg. 1980;59:377.
Fink E, Brandom BW, Torp KD. Heatstroke in the super-sized athlete. Pediatr Emerg Care. 2006;22:510.
Poussel M, Guerci P, Kaminsky P, Heymonet M, Roux-Buisson N, Faure J, et al. Exertional heat stroke and susceptibility to malignant hyperthermia in an athlete: evidence for a link? J Athl Train. 2015;50:1212–4.
Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet. 1991;338:1491–2.
Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg. 2009;109:1065.
Muldoon S, Deuster P, Voelkel M, Capacchione J, Bunger R. Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia: is there a link? Curr Sports Med Rep. 2008;7:74.
Muldoon S, Deuster P, Brandom B, Bunger R. Is there a link between malignant hyperthermia and exertional heat illness? Exerc Sport Sci Rev. 2004;32:174.
Laitano O, Leon LR, Roberts WO, Sawka MN. Controversies in exertional heat stroke diagnosis, prevention, and treatment. J Appl Physiol. 2019;127:1338–48.
Sagui E, Montigon C, Abriat A, Jouvion A, Duron-Martinaud S, Canini F, et al. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? PLoS ONE. 2015;10:e0135496.
Nybo L, Rasmussen P, Sawka MN. Performance in the heat-physiological factors of importance for hyperthermia-induced fatigue. Compr Physiol. 2014;4:657–89.
González-Alonso J, Crandall CG, Johnson JM. The cardiovascular challenge of exercising in the heat. J Physiol (Lond). 2008;586:45–53.
Casa DJ, DeMartini JK, Bergeron MF, Csillan D, Eichner ER, Lopez RM, et al. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2015;50:986–1000.
Binkley HM, Beckett J, Casa DJ, Kleiner DM, Plummer PE. National athletic trainers’ association position statement: exertional heat illnesses. J Athl Train. 2002;37:329–43.
Smith JE. Cooling methods used in the treatment of exertional heat illness. Br J Sports Med. 2005;39:503–7.
Larach MG, Rosenberg H, Larach DR, Broennle AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology. 1987;66:547–50.
Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417–20.
Campbell IT, Ellis FR, Evans RT. Metabolic rate and blood hormone and metabolite levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise. Anesthesiology. 1981;55:46–52.
Leon LR, Gordon CJ, Helwig BG, Rufolo DM, Blaha MD. Thermoregulatory, behavioral, and metabolic responses to heatstroke in a conscious mouse model. Am J Physiol Regul Integr Comp Physiol. 2010;299:R241–248.
King MA, Ward MD, Mayer TA, Plamper ML, Madsen CM, Cheuvront SN, et al. Influence of prior illness on exertional heat stroke presentation and outcome. PLoS ONE. 2019;14:e0221329.
Roberts WO, Dorman JC, Bergeron MF. Recurrent heat stroke in a runner: race simulation testing for return to activity. Med Sci Sports Exerc. 2016;48:785–9.
Howe AS, Boden BP. Heat-related illness in athletes. Am J Sports Med. 2007;35:1384–95.
Knight N, Parkin J, Smith R, Kipps C. The incidence of exertional heat stroke during mass-participation triathlon races: optimising athlete safety. Br J Sports Med. 2017;51:344–5.
Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110:89–94.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524368/
Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010;23:417–22.
Monnier N, Krivosic-Horber R, Payen J-F, Kozak-Ribbens G, Nivoche Y, Adnet P, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002;97:1067–74.
Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue. Can J Anaesth. 1997;44:696–701.
Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. Anesth Analg. 2009;109:1162–6.
Harmer AR, Ruell PA, Hunter SK, McKenna MJ, Thom JM, Chisholm DJ, et al. Effects of type 1 diabetes, sprint training and sex on skeletal muscle sarcoplasmic reticulum Ca2+ uptake and Ca2+-ATPase activity. J Physiol (Lond). 2014;592:523–35.
Dhaese HL, Martens PR, Müller NH, Casier IM, Mulier JPJ, Heytens L. The use of emergency medical cooling system pads in the treatment of malignant hyperthermia. Eur J Anaesthesiol. 2010;27:83–5.
Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62–5.
Fiszer D, Shaw M-A, Fisher NA, Carr IM, Gupta PK, Watkins EJ, et al. Next-generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness. Anesthesiology. 2015;122:1033–46.
Mungunsukh O, Deuster P, Muldoon S, O’Connor F, Sambuughin N. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data. Br J Anaesth. 2019;123:e461–e463463.
Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168–80.
Protasi F, Paolini C, Dainese M. Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke. J Physiol (Lond). 2009;587:3095–100.
Lydiatt JS, Hill GE. Treatment of heat stroke with dantrolene. JAMA. 1981;246:41–2.
Tayeb OS, Marzouki ZM. Effect of dantrolene pretreatment on heat stroke in sheep. Pharmacol Res. 1990;22:565–72.
Channa AB, Seraj MA, Saddique AA, Kadiwal GH, Shaikh MH, Samarkandi AH. Is dantrolene effective in heat stroke patients? Crit Care Med. 1990;18:290–2.
Bouchama A, Cafege A, Devol EB, Labdi O, El-Assil K, Seraj M. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med. 1991;19:176–80.
Moran D, Epstein Y, Wiener M, Horowitz M. Dantrolene and recovery from heat stroke. Aviat Space Environ Med. 1999;70:987–9.
Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2:895–8.
Ellis FR, Harriman DG, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth. 1971;43:721–2.
Kalow W, Britt BA, Richter A. The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can Anaesth Soc J. 1977;24:678–94.
Bendahan D, Guis S, Monnier N, Kozak-Ribbens G, Lunardi J, Ghattas B, et al. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand. 2004;48:1019–27.
The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth. 1984;56:1267–9.
Zullo A, Textor M, Elischer P, Mall S, Alt A, Klingler W, et al. Voltage modulates halothane-triggered Ca2+ release in malignant hyperthermia-susceptible muscle. J Gen Physiol. 2018;150:111–25.
Klein MG, Simon BJ, Schneider MF. Effects of caffeine on calcium release from the sarcoplasmic reticulum in frog skeletal muscle fibres. J Physiol (Lond). 1990;425:599–626.
Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115:531–9.
Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41:955–66.
Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology. 1998;88:579–88.
Kindler CH, Girard T, Gong D, Urwyler A. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia. Anesth Analg. 2002;94:1028–33.
Heytens L, Martin JJ, Van de Kelft E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth. 1992;68:72–5.
Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O. Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth. 2000;14:6–13.
Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–9.
Wappler F, Roewer N, Kochling A, Scholz J, Loscher W, Steinfath M, et al. Effects of the Serotonin2Receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology. 1996;84:1280–7.
Lee MA, McGlinch EB, McGlinch MC, Capacchione JF. Malignant hyperthermia susceptibility and fitness for duty. Mil Med. 2017;182:e1854–e18571857.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Zvaritch E, Gillies R, Kraeva N, Richer M, Jungbluth H, Riazi S. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Can J Anaesth. 2019;66:540–5.
Hunter SL, Rosenberg H, Tuttle GH, DeWalt JL, Smodic R, Martin J. Malignant hyperthermia in a college football player. Phys Sportsmed. 1987;15:77–81.
Pamukcoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol. 1988;9:161–2.
Kozak-Ribbens G, Bendahan D, Rodet L, Confort-Gouny S, Miri A, Talmant A, et al. Metabolic events with spontaneous malignant hyperthermia crisis in an anaesthetized pig. Can J Anaesth. 1997;44:757–64.
Gatz EE, Wingard DW. Malignant hyperthermia. Nebr Med J. 1973;58:434–7.
Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology. 2011;115:938–45.
Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci. 1973;62:948–51.
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene–a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364–73.
Acknowledgements
We thank Mr. Lucas de Carvalho for technical contributions with the illustration.
Disclaimers
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations.
Author information
Authors and Affiliations
Department of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, 1864 Stadium Road, Room 100, Gainesville, FL, USA
Orlando Laitano & Kevin O. Murray
Thermal and Mountain Medicine Division, US Army Research Institute for Environmental Medicine, Natick, MA, USA
Lisa R. Leon
- Orlando Laitano
You can also search for this author inPubMed Google Scholar
- Kevin O. Murray
You can also search for this author inPubMed Google Scholar
- Lisa R. Leon
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toOrlando Laitano.
Ethics declarations
Funding
No sources of funding were used to assist in the preparation of this article.
Conflict of Interest
Orlando Laitano (OL), Kevin O. Murray (KOM) and Lisa R. Leon (LRL) declare that they have no conflicts of interest relevant to the content of this review.
Authorship Contributions
OL and LRL outlined and wrote the first draft of the manuscript. KOM analyzed, interpreted the literature and wrote the section on IVCT. OL, KOM and LRL revised the original manuscript. All authors read and approved the final version of the manuscript.
Rights and permissions
About this article
Cite this article
Laitano, O., Murray, K.O. & Leon, L.R. Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture.Sports Med50, 1581–1592 (2020). https://doi.org/10.1007/s40279-020-01318-4
Published:
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative